These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 18828523)

  • 1. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Bagg AS; Lockey RF
    Clin Allergy Immunol; 2008; 21():455-68. PubMed ID: 18828523
    [No Abstract]   [Full Text] [Related]  

  • 2. Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.
    Bukantz SC; Lockey RF
    Clin Allergy Immunol; 2004; 18():711-27. PubMed ID: 15042944
    [No Abstract]   [Full Text] [Related]  

  • 3. Instructions and consent forms for subcutaneous allergen immunotherapy.
    Cox L; Lockey RF
    Clin Allergy Immunol; 2008; 21():499-525. PubMed ID: 18828526
    [No Abstract]   [Full Text] [Related]  

  • 4. Anaphylactic reactions during immunotherapy.
    Rezvani M; Bernstein DI
    Immunol Allergy Clin North Am; 2007 May; 27(2):295-307, viii. PubMed ID: 17493504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local reactions from subcutaneous allergen immunotherapy.
    Coop CA
    Immunotherapy; 2013 Dec; 5(12):1339-45. PubMed ID: 24283844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous Immunotherapy Safety: Incidence per Surveys and Risk Factors.
    Sánchez-Borges M; Bernstein DI; Calabria C
    Immunol Allergy Clin North Am; 2020 Feb; 40(1):25-39. PubMed ID: 31761119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
    Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM
    Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allergen immunotherapy: an updated review of safety.
    James C; Bernstein DI
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):55-59. PubMed ID: 27906697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The mechanisms of allergen-specific immunotherapy more clear].
    Rak S
    Lakartidningen; 2008 Jun 25-Jul 1; 105(26-27):1935-7. PubMed ID: 18681375
    [No Abstract]   [Full Text] [Related]  

  • 10. Preparing and mixing allergen vaccines for subcutaneous immunotherapy.
    Nelson HS
    Clin Allergy Immunol; 2008; 21():303-20. PubMed ID: 18828513
    [No Abstract]   [Full Text] [Related]  

  • 11. Adverse effects associated with sublingual immunotherapy.
    Passalacqua G; Valovirta E
    Clin Allergy Immunol; 2008; 21():469-75. PubMed ID: 18828524
    [No Abstract]   [Full Text] [Related]  

  • 12. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
    Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
    Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allergen-related approaches to immunotherapy.
    Rolland JM; Gardner LM; O'Hehir RE
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention and treatment of anaphylaxis.
    Kemp SF; deShazo RD
    Clin Allergy Immunol; 2008; 21():477-98. PubMed ID: 18828525
    [No Abstract]   [Full Text] [Related]  

  • 15. Anaphylaxis caused by allergen sublingual immunotherapy?
    André C; Fadel R
    Allergy; 2007 Oct; 62(10):1220-1. PubMed ID: 17845597
    [No Abstract]   [Full Text] [Related]  

  • 16. The safety of allergen immunotherapy: a literature review.
    Cook PR; Farias C
    Ear Nose Throat J; 1998 May; 77(5):378-9, 383-8. PubMed ID: 9615518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel routes for allergen immunotherapy: safety, efficacy and mode of action.
    Moingeon P; Mascarell L
    Immunotherapy; 2012 Feb; 4(2):201-12. PubMed ID: 22339462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
    Wilcock LK; Francis JN; Durham SR
    Immunol Allergy Clin North Am; 2006 May; 26(2):333-47, viii-ix. PubMed ID: 16701148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis due to olive fruit after pollen immunotherapy.
    Feo Brito F; Mur Gimeno P; Bartolomé B; Castro A; Guerra F
    J Investig Allergol Clin Immunol; 2011; 21(2):160-1. PubMed ID: 21462812
    [No Abstract]   [Full Text] [Related]  

  • 20. Current status of allergen immunotherapy. Shortened version of a World Health Organisation/International Union of Immunological Societies Working Group Report.
    Lancet; 1989 Feb; 1(8632):259-61. PubMed ID: 2563421
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 33.